Juan Carlos Lopez-Talavera, MD, PhD, brings over 20 years of leadership experience in managing registrational clinical trials and advancing patient engagement for approved therapeutics. He has played a pivotal role in the development and regulatory approvals of several treatments across the USA, Europe, and Asia, including COPEGUS® (ribavirin), YERVOY® (ipilimumab), ELIQUIS® (apixaban), OPDIVO® (nivolumab), VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir), and OCALIVA® (obeticholic acid).

Before joining Anavex, Dr. Lopez-Talavera held leadership roles at Fractyl Health, Intercept Pharmaceuticals, AbbVie, Bristol Myers Squibb, and Roche. Earlier in his career, he was an Assistant Professor at the University of Pittsburgh Medical Center and a postdoctoral fellow at Yale University. Dr. Lopez-Talavera earned his PhD while collaborating with Nobel laureates Sir Michael Houghton, PhD, and Harvey Alter, MD, contributing to the groundbreaking discovery of the hepatitis C virus (HCV).